Cargando…
Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients
Prophylactic donor lymphocyte infusion (DLI) starting at 6 months after T cell-depleted allogeneic stem cell transplantation (TCD-alloSCT) can introduce a graft-versus-leukemia (GvL) effects with low risk of severe graft-versus-host-disease (GvHD). We established a policy to apply low-dose early DLI...
Autores principales: | van der Zouwen, Boris, Koster, E. A. S., von dem Borne, P. A., Oosten, L. E. M., Roza-Scholten, M. W. I., Snijders, T. J. F., van Lammeren, D., van Balen, P., Marijt, W. A. F., Veelken, H., Falkenburg, J. H. F., de Wreede, L. C., Halkes, C. J. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102042/ https://www.ncbi.nlm.nih.gov/pubmed/36881136 http://dx.doi.org/10.1007/s00277-023-05145-1 |
Ejemplares similares
-
Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusion
por: Koster, Eva A. S., et al.
Publicado: (2023) -
Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction
por: van Balen, Peter, et al.
Publicado: (2018) -
The allogeneic HLA-DP-restricted T-cell repertoire provoked by allogeneic dendritic cells contains T cells that show restricted recognition of hematopoietic cells including primary malignant cells
por: Laghmouchi, Aicha, et al.
Publicado: (2019) -
P819: TRANSPLANT, TREATMENT AND TRANSFUSION FREE (TTT-FREE) SURVIVAL AS RELEVANT CLINICAL ENDPOINT AFTER IMMUNOSUPPRESSIVE TREATMENT FOR ACQUIRED APLASTIC ANEMIA IN ADULTS
por: Koster, E., et al.
Publicado: (2022) -
HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study
por: van Balen, Peter, et al.
Publicado: (2020)